These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 35055244)

  • 21. Rational application of nanoadjuvant for mucosal vaccine delivery system.
    Dewangan HK
    J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways.
    Li M; Zhao M; Fu Y; Li Y; Gong T; Zhang Z; Sun X
    J Control Release; 2016 Apr; 228():9-19. PubMed ID: 26941035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.
    Henderson A; Propst K; Kedl R; Dow S
    Vaccine; 2011 Jul; 29(32):5304-12. PubMed ID: 21600950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.
    Timothy AA; Tokanovic A; Snibson KJ; Edwards SJ; Pearse MJ; Scheerlinck JP; Sutton P
    Hum Vaccin Immunother; 2015; 11(2):377-85. PubMed ID: 25692970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nasal vaccines].
    Kido H; Mizuno D; Takei T
    Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buccal and sublingual vaccine delivery.
    Kraan H; Vrieling H; Czerkinsky C; Jiskoot W; Kersten G; Amorij JP
    J Control Release; 2014 Sep; 190():580-92. PubMed ID: 24911355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems.
    Cho CS; Hwang SK; Gu MJ; Kim CG; Kim SK; Ju DB; Yun CH; Kim HJ
    Tissue Eng Regen Med; 2021 Oct; 18(5):693-712. PubMed ID: 34304387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Reflex Defense Mechanisms of Upper Airway Mucosa: Possible Clinical Application.
    Pedan H; Janosova V; Hajtman A; Calkovsky V
    Physiol Res; 2020 Mar; 69(Suppl 1):S55-S67. PubMed ID: 32228012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.
    Feng F; Wen Z; Chen J; Yuan Y; Wang C; Sun C
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.
    Bakkari MA; Valiveti CK; Kaushik RS; Tummala H
    Mol Pharm; 2021 Jun; 18(6):2233-2241. PubMed ID: 34010002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.
    Pavot V; Climent N; Rochereau N; Garcia F; Genin C; Tiraby G; Vernejoul F; Perouzel E; Lioux T; Verrier B; Paul S
    Biomaterials; 2016 Jan; 75():327-339. PubMed ID: 26539801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticles for nasal vaccination.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Adv Drug Deliv Rev; 2009 Feb; 61(2):140-57. PubMed ID: 19121350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.
    Calderon-Nieva D; Goonewardene KB; Gomis S; Foldvari M
    Drug Deliv Transl Res; 2017 Aug; 7(4):558-570. PubMed ID: 28639138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.